Photo from wikipedia
The shrinking drug pipeline for antibacterial drugs has made it very precious to discover and develop novel drugs in this space. In this context, the recent approvals of β lactamase… Click to show full abstract
The shrinking drug pipeline for antibacterial drugs has made it very precious to discover and develop novel drugs in this space. In this context, the recent approvals of β lactamase inhibitors with either cephalosporin or penem as combination drugs are welcome news to the community. There are number of β lactamase inhibitors with suggested partnered drugs that are currently in various stages of drug development. The focus of this manuscript is to provide some perspectives on clinical pharmacology considerations that may aid in the successful development of such combination drugs. In this regard, a broad framework which includes pharmacokinetics (PK), pharmacodynamics (PD) and PK/PD guided surrogate strategies are provided to enable an informed dosing decision of the combination agent.
Journal Title: Drug research
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!